Dual inhibition of MEK1/2 and EGFR synergistically induces caspase-3-dependent apoptosis in EGFR inhibitor-resistant lung cancer cells via BIM upregulation

Investigational New Drugs

Volumn 31, Issue 6, 2013, Pages 1458-1465

  Song, Ji Young ^a   Kim, Choung Soo ^a   Lee, Je Hwan ^a   Jang, Se Jin ^a   Lee, Sang Wook ^a   Hwang, Jung Jin ^a   Lim, Chulsoo ^b   Lee, Gilnam ^b   Seo, Jeongbeob ^b   Cho, Suk Young ^b   Choi, Jene ^a  

^a University of Ulsan College of Medicine   (South Korea)

^b Chemizon A Division of Optomagic CO Ltd   (South Korea)

Author keywords

CZ0775; EGFR tyrosine kinase inhibitor; Lapatinib; Lung cancer; MEK1 2 inhibitor; Selumetinib

Indexed keywords

ANTINEOPLASTIC AGENT; BIM PROTEIN; CASPASE 3; CZ 0775; EPIDERMAL GROWTH FACTOR RECEPTOR; EPIDERMAL GROWTH FACTOR RECEPTOR KINASE INHIBITOR; LAPATINIB; LIPOCORTIN 5; MITOGEN ACTIVATED PROTEIN KINASE; MITOGEN ACTIVATED PROTEIN KINASE KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE KINASE 1 INHIBITOR; MITOGEN ACTIVATED PROTEIN KINASE KINASE 2; MITOGEN ACTIVATED PROTEIN KINASE KINASE 2 INHIBITOR; PROTEIN SERINE THREONINE KINASE INHIBITOR; SELUMETINIB; SMALL INTERFERING RNA; SURVIVIN; UNCLASSIFIED DRUG;

APOPTOSIS; ARTICLE; CANCER CELL; CANCER CELL CULTURE; CANCER RESISTANCE; CELL COUNT; CELL LABELING; CELL PROLIFERATION; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG CYTOTOXICITY; DRUG POTENTIATION; DRUG STRUCTURE; ENZYME ACTIVITY; ENZYME INHIBITION; GENE MUTATION; HUMAN; HUMAN CELL; IC 50; IN VITRO STUDY; LUNG NON SMALL CELL CANCER; MONOTHERAPY; PRIORITY JOURNAL; PROTEIN DEPLETION; PROTEIN EXPRESSION; PROTEIN INDUCTION; UPREGULATION;

ANTINEOPLASTIC AGENTS; APOPTOSIS; APOPTOSIS REGULATORY PROTEINS; BENZIMIDAZOLES; CARCINOMA, NON-SMALL-CELL LUNG; CASPASE 3; CELL LINE, TUMOR; DRUG SYNERGISM; HUMANS; LUNG NEOPLASMS; MAP KINASE KINASE 1; MAP KINASE KINASE 2; MEMBRANE PROTEINS; MUTATION; PROTEIN KINASE INHIBITORS; PROTO-ONCOGENE PROTEINS; PYRIDONES; QUINAZOLINES; RECEPTOR, EPIDERMAL GROWTH FACTOR; SULFONAMIDES;

EID: 84888610822     PISSN: 01676997     EISSN: 15730646     Source Type: Journal    
DOI: 10.1007/s10637-013-0030-0     Document Type: Article

References (33)

1. Parkin DM, Bray F, Ferlay J, Pisani P (2005) Global cancer statistics, 2002. CA Cancer J Clin 55(2):74-108
2. Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D (2011) Global cancer statistics. CA Cancer J Clin 61(2):69-90. doi: 10.3322/caac.20107
3. Lynch TJ, Bell DW, Sordella R, Gurubhagavatula S, Okimoto RA, Brannigan BW, Harris PL, Haserlat SM, Supko JG, Haluska FG, Louis DN, Christiani DC, Settleman J, Haber DA (2004) Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. N Engl J Med 350(21):2129-2139
4. Paez JG, Janne PA, Lee JC, Tracy S, Greulich H, Gabriel S, Herman P, Kaye FJ, Lindeman N, Boggon TJ, Naoki K, Sasaki H, Fujii Y, Eck MJ, Sellers WR, Johnson BE, Meyerson M (2004) EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy. Science 304(5676):1497-1500
5. Mitsudomi T, Yatabe Y (2007) Mutations of the epidermal growth factor receptor gene and related genes as determinants of epidermal growth factor receptor tyrosine kinase inhibitors sensitivity in lung cancer. Cancer Sci 98(12):1817-1824
6. Mok TS (2011) Personalized medicine in lung cancer: what we need to know. Nat Rev Clin Oncol 8(11):661-668. doi: 10.1038/nrclinonc.2011.126
7. Yoon S, Seger R (2006) The extracellular signal-regulated kinase: multiple substrates regulate diverse cellular functions. Growth Factors 24(1):21-44
8. Pao W, Wang TY, Riely GJ, Miller VA, Pan Q, Ladanyi M, Zakowski MF, Heelan RT, Kris MG, Varmus HE (2005) KRAS mutations and primary resistance of lung adenocarcinomas to gefitinib or erlotinib. PLoS Med 2(1):e17
9. Gazdar AF, Shigematsu H, Herz J, Minna JD (2004) Mutations and addiction to EGFR: the Achilles 'heal' of lung cancers? Trends Mol Med 10(10):481-486
10. Thomas RK, Baker AC, Debiasi RM, Winckler W, Laframboise T et al (2007) High-throughput oncogene mutation profiling in human cancer. Nat Genet 39(3):347-351
11. Kancha RK, von Bubnoff N, Bartosch N, Peschel C, Engh RA, Duyster J (2011) Differential sensitivity of ERBB2 kinase domain mutations towards lapatinib. PLoS One 6(10):e26760. doi: 10.1371/journal.pone.0026760
12. Medina PJ, Goodin S (2008) Lapatinib: a dual inhibitor of human epidermal growth factor receptor tyrosine kinases. Clin Ther 30(8):1426-1447. doi: 10.1016/j.clinthera.2008.08.008
13. Ross HJ, Blumenschein GR Jr, Aisner J, Damjanov N, Dowlati A, Garst J, Rigas JR, Smylie M, Hassani H, Allen KE, Leopold L, Zaks TZ, Shepherd FA (2010) Randomized phase II multicenter trial of two schedules of lapatinib as first- or second-line monotherapy in patients with advanced or metastatic non-small cell lung cancer. Clin Cancer Res 16(6):1938-1949. doi: 10.1158/1078-0432.CCR-08-3328
14. Hainsworth JD, Cebotaru CL, Kanarev V, Ciuleanu TE, Damyanov D, Stella P, Ganchev H, Pover G, Morris C, Tzekova V (2010) A phase II, open-label, randomized study to assess the efficacy and safety of AZD6244 (ARRY-142886) versus pemetrexed in patients with non-small cell lung cancer who have failed one or two prior chemotherapeutic regimens. J Thorac Oncol 5(10):1630-1636. doi: 10.1097/JTO.0b013e3181e8b3a3
15. Yoon J, Koo KH, Choi KY (2011) MEK1/2 inhibitors AS703026 and AZD6244 may be potential therapies for KRAS mutated colorectal cancer that is resistant to EGFR monoclonal antibody therapy. Cancer Res 71(2):445-453. doi: 10.1158/0008-5472.CAN-10-3058
16. Sebolt-Leopold JS, Dudley DT, Herrera R, Van Becelaere K, Wiland A, Gowan RC, Tecle H, Barrett SD, Bridges A, Przybranowski S, Leopold WR, Saltiel AR (1999) Blockade of the MAP kinase pathway suppresses growth of colon tumors in vivo. Nat Med 5(7):810-816
17. Ciuffreda L, Del Bufalo D, Desideri M, Di Sanza C, Stoppacciaro A, Ricciardi MR, Chiaretti S, Tavolaro S, Benassi B, Bellacosa A, Foà R, Tafuri A, Cognetti F, Anichini A, Zupi G, Milella M (2009) Growth-inhibitory and antiangiogenic activity of the MEK inhibitor PD0325901 in malignant melanoma with or without BRAF mutations. Neoplasia 11(8):720-731
18. Friday BB, Adjei AA (2008) Advances in targeting the Ras/Raf/MEK/Erk mitogen-activated protein kinase cascade with MEK inhibitors for cancer therapy. Clin Cancer Res 14(2):342-346. doi: 10.1158/1078-0432.CCR-07-4790
19. Yoon YK, Kim HP, Han SW, Oh do Y, Im SA, Bang YJ, Kim TY (2010) KRAS mutant lung cancer cells are differentially responsive to MEK inhibitor due to AKT or STAT3 activation: implication for combinatorial approach. Mol Carcinog 49(4):353-362. doi: 10.1002/mc.20607
20. Li H, Zhou S, Li X, Wang D, Wang Y, Zhou C, Schmid-Bindert G (2012) Gefitinib-resistance is related to BIM expression in non-small cell lung cancer cell lines. Cancer Biother Radiopharm 28(2):115-123. doi: 10.1089/cbr.2012.1268
21. Cragg MS, Harris C, Strasser A, Scott CL (2009) Unleashing the power of inhibitors of oncogenic kinases through BH3 mimetics. Nat Rev Cancer 9(5):321-326. doi: 10.1038/nrc2615
22. Cragg MS, Jansen ES, Cook M, Harris C, Strasser A, Scott CL (2008) Treatment of B-RAF mutant human tumor cells with a MEK inhibitor requires Bim and is enhanced by a BH3 mimetic. J Clin Invest 118(11):3651-3659. doi: 10.1172/JCI35437
23. Yeh JJ, Routh ED, Rubinas T, Peacock J, Martin TD, Shen XJ, Sandler RS, Kim HJ, Keku TO, Der CJ (2009) KRAS/BRAF mutation status and ERK1/2 activation as biomarkers for MEK1/2 inhibitor therapy in colorectal cancer. Mol Cancer Ther 8(4):834-843. doi: 10.1158/1535-7163.MCT-08-0972
24. Ayoola A, Barochia A, Belani K, Belani CP (2012) Primary and acquired resistance to epidermal growth factor receptor tyrosine kinase inhibitors in non-small cell lung cancer: an update. Cancer Invest 30(5):433-446. doi: 10.3109/07357907.2012.666691
25. Kim KB, Kefford R, Pavlick AC, Infante JR, Ribas A, Sosman JA, Fecher LA, Millward M, McArthur GA, Hwu P, Gonzalez R, Ott PA, Long GV, Gardner OS, Ouellet D, Xu Y, DeMarini DJ, Le NT, Patel K, Lewis KD (2013) Phase II study of the MEK1/MEK2 inhibitor trametinib in patients with metastatic BRAF-mutant cutaneous melanoma previously treated with or without a BRAF inhibitor. J Clin Oncol 31(4):482-489. doi: 10.1200/JCO.2012.43.5966
26. Metro G, Chiari R, Baldi A, De Angelis V, Minotti V, Crinò L (2013) Selumetinib: a promising pharmacologic approach for KRAS-mutant advanced non-small-cell lung cancer. Future Oncol 9(2):167-177. doi: 10.2217/fon.12.198
27. Meloche S, Pouysségur J (2007) The ERK1/2 mitogen-activated protein kinase pathway as a master regulator of the G1- to S-phase transition. Oncogene 26(22):3227-3239
28. Balmanno K, Cook SJ (2009) Tumour cell survival signalling by the ERK1/2 pathway. Cell Death Differ 16(3):368-377. doi: 10.1038/cdd.2008.148
29. Gillings AS, Balmanno K, Wiggins CM, Johnson M, Cook SJ (2009) Apoptosis and autophagy: BIM as a mediator of tumour cell death in response to oncogene-targeted therapeutics. FEBS J 276(21):6050-6062. doi: 10.1111/j.1742-4658.2009.07329.x
30. Schulze A, Lehmann K, Jefferies HB, McMahon M, Downward J (2001) Analysis of the transcriptional program induced by Raf in epithelial cells. Genes Dev 15(8):981-994
31. Troiani T, Vecchione L, Martinelli E, Capasso A, Costantino S, Ciuffreda LP, Morgillo F, Vitagliano D, D'Aiuto E, De Palma R, Tejpar S, Van Cutsem E, De Lorenzi M, Caraglia M, Berrino L, Ciardiello F (2012) Intrinsic resistance to selumetinib, a selective inhibitor of MEK1/2, by cAMP-dependent protein kinase A activation in human lung and colorectal cancer cells. Br J Cancer 106(10):1648-1659. doi: 10.1038/bjc.2012.129
32. Little AS, Balmanno K, Sale MJ, Smith PD, Cook SJ (2012) Tumour cell responses to MEK1/2 inhibitors: acquired resistance and pathway remodelling. Biochem Soc Trans 40(1):73-78. doi: 10.1042/BST20110647
33. Jänne PA, Shaw AT, Pereira JR, Jeannin G, Vansteenkiste J, Barrios C, Franke FA, Grinsted L, Zazulina V, Smith P, Smith I, Crinò L (2013) Selumetinib plus docetaxel for KRAS-mutant advanced non-small-cell lung cancer: a randomised, multicentre, placebo-controlled, phase 2 study. Lancet Oncol 14(1):38-47. doi: 10.1016/S1470-2045(12)70489-8